Abstract
The metal bonding properties of some ARA-II (Angiotensin II Receptor Antagonists) compounds, such as valsartan (VAL), were investigated by using spectrofluorimetric method. Fluorescence quenching of VAL by Cu(II) was studied and optimal experimental conditions were determined. The excitation and emission wavelengths were λex= 280 nm and λem= 436 nm for the Cu(II)-VAL complex in methanol medium. The calibration curve was obtained from Stern-Volmer equation plotting to F0/F-[Cu+2] graphs and the linearity was found within the range of 0.25-2.54 μg.ml-1 for the Cu(II)-VAL complex under optimal conditions. The detection limit (LOD) and the quantitation limits (LOQ) of the proposed method for this complex were 4.96 ng.ml-1 and 16.53 ng.ml-1 respectively. The stochiometry of this complex was also determined by using the continuous variation method and the molar ratio of Cu(II):VAL was calculated as 1:1. The interaction between the valsartan in tablet form and Cu(II) in the vitamin-mineral combination tablet was investigated by applying this quenching method and obtained satisfactory results.
Keywords: Valsartan, Cu(II) complex, fluorescence quenching, pharmaceutical analysis.
Current Drug Therapy
Title:Investigation of the Metal Bonding Properties of Some ARA-II Compounds Using Spectrofluorimetric Method
Volume: 9 Issue: 4
Author(s): S. Beniz Gunduz and Ahmet Donertas
Affiliation:
Keywords: Valsartan, Cu(II) complex, fluorescence quenching, pharmaceutical analysis.
Abstract: The metal bonding properties of some ARA-II (Angiotensin II Receptor Antagonists) compounds, such as valsartan (VAL), were investigated by using spectrofluorimetric method. Fluorescence quenching of VAL by Cu(II) was studied and optimal experimental conditions were determined. The excitation and emission wavelengths were λex= 280 nm and λem= 436 nm for the Cu(II)-VAL complex in methanol medium. The calibration curve was obtained from Stern-Volmer equation plotting to F0/F-[Cu+2] graphs and the linearity was found within the range of 0.25-2.54 μg.ml-1 for the Cu(II)-VAL complex under optimal conditions. The detection limit (LOD) and the quantitation limits (LOQ) of the proposed method for this complex were 4.96 ng.ml-1 and 16.53 ng.ml-1 respectively. The stochiometry of this complex was also determined by using the continuous variation method and the molar ratio of Cu(II):VAL was calculated as 1:1. The interaction between the valsartan in tablet form and Cu(II) in the vitamin-mineral combination tablet was investigated by applying this quenching method and obtained satisfactory results.
Export Options
About this article
Cite this article as:
Gunduz Beniz S. and Donertas Ahmet, Investigation of the Metal Bonding Properties of Some ARA-II Compounds Using Spectrofluorimetric Method, Current Drug Therapy 2014; 9 (4) . https://dx.doi.org/10.2174/1574885510999150505165817
DOI https://dx.doi.org/10.2174/1574885510999150505165817 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systematic Evaluation of Drug-Loaded Hydrogels for Application in Osteosarcoma Treatment
Current Pharmaceutical Biotechnology Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers
Medicinal Chemistry NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Effects of Agaricus Blazei Extract Plus Lactoferrin or Lactoferrin Alone on Tumor Growth and UFT-Induced Adverse Reactions in Sarcoma 180- or Highly Metastatic Osteosarcoma LM8-Bearing Mice
The Natural Products Journal Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells
Current Pharmaceutical Design Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals The Role of Platelets in Bone Remodeling
Inflammation & Allergy - Drug Targets (Discontinued) A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets Doxorubicin Action on Mitochondria: Relevance to Osteosarcoma Therapy?
Current Drug Targets Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway
Current Drug Targets Lactoferrin in Bone Tissue Regeneration
Current Medicinal Chemistry Targeting Invasion Induction as a Therapeutic Strategy for the Treatment of Cancer
Current Cancer Drug Targets C-20 Cyclopropyl Vitamin D3 Analogs
Current Topics in Medicinal Chemistry Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design Function Analysis of Human Protein Interactions Based on a Novel Minimal Loop Algorithm
Current Bioinformatics Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy